---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-062257"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T21:17:48.307937+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics doses first participants in Phase 1a trial of anti-tau antibody VY-TAU01 for Alzheimer's

## Summary
- First participants dosed in Phase 1a SAD trial of VY-TAU01, an anti-tau antibody for Alzheimer's disease.
- Trial is randomized, double-blind, placebo-controlled, evaluating safety and PK in healthy adult volunteers.
- Study conducted at a single U.S. site; expected to enroll approximately 48 patients across multiple cohorts.
- VY-TAU01 designed to inhibit spread of pathological tau in Alzheimer's disease.

## SEC filing metadata
- accession: 0001104659-24-062257
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465924062257/0001104659-24-062257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465924062257/tm2414591d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-062257
- JSON: https://secwatch.observer/filing/0001104659-24-062257.json
- Plain text: https://secwatch.observer/filing/0001104659-24-062257.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.